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Mutations in the MUTYH gene have been reported to be associated with increased risk of developing colorectal cancer. In this study,
we confirmed this association using original data on 928 colorectal cancer cases and 845 healthy controls from Scotland. We then
conducted a meta-analysis from published data on the association between mutations at MUTYH and colorectal cancer risk. We
show for the first time a small but significant mono-allelic effect with a genotype relative risk (GRR) of 1.27 (95% confidence interval
(CI): 1.01–1.61), and confirm and give a more precise estimate of the strong bi-allelic effect with an estimated GRR of 117 (95% CI:
74–184). This study underscores the need for large sample sizes in order to identify small gene effects when the disease allele
frequency is low.
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DNA repair genes are strong candidate cancer susceptibility genes
(Ames and Gold, 1991; Yoshimura et al, 2003). One such gene
is MUTYH, which together with OGG1 and MTH1 is a key
component of the base-excision repair (BER) pathway. The main
function of the BER pathway is to repair DNA oxidative damage
caused by aerobic metabolism. Hence, MUTYH has raised much
interest among those trying to unravel the genetic contribution to
cancer risk (Al-Tassan et al, 2004; Tao et al, 2004; Farrington et al,
2005).
MUTYH has been associated with multiple colorectal adenomas
(Al-Tassan et al, 2002) and with colorectal adenocarcinomas
(Croitoru et al, 2004; Farrington et al, 2005). Here, we present a
replication study in the Scottish population and a meta-analysis of
published case–control data on MUTYH and colorectal cancer.
Both types of study are important, because genetic association
studies involving complex traits are frequently inconclusive owing
to the difficulty of isolating the causal variant effect from other
confounding factors. Hence, replication of the original findings is
needed to support the validity of the association. Nevertheless, this
might not always be possible, as unrealistically large follow-up
studies would be required to detect small gene effects and in such
instances the meta-analysis of published data may clarify the
credibility of any inconclusive association.
MATERIALS AND METHODS
Replication data
We previously reported an association between MUTYH and
colorectal cancer in a population-based study of 2239 cases (with
histologically confirmed adenocarcinomas) and 1845 controls in
Scotland. MUTYH homozygous mutation carriers had a 90-fold
excess risk, whereas heterozygous carriers had no significant
increased risk compared to wild-type homozygous on the overall
cohort (Table 1), although there was a significant heterozygous
effect in the late-onset cohort. Here, we extend this population-
based study to include a further 928 colorectal cancer cases and
845 healthy controls. These samples were collected from the
general population of Scotland. Cases were ascertained through all
surgical Units in Scotland dealing with colorectal cancer. All cases
had histologically confirmed adenocarcinoma of the colon or
rectum. Blood DNA samples were obtained from the patients after
fully informed consent. The study is subject to approvals from the
Multi Centre Research Ethics Committee and all relevant Local
Ethics Research Committee, as well as approval from NHS R&D
Management for every participating hospital.
The two most common MUTYH variants in the Scottish
population, Y165C and G382D, were genotyped following methods
described previously (Farrington et al, 2005). Genotypes were
coded as MM if the person was an Y165C/Y165C or G382D/G382D
homozygote or Y165C/G382D or other compound heterozygote
(detected by sequencing the entire coding region of the second
allele of G382D/Y165C heterozygotes); as WM if the person was an
Y165C or G382D heterozygote and otherwise as WW. All cases and
67% of controls were screened for a second mutation if they
happened to be an Y165C or G382D heterozygote. Owing to the low
frequency of compound heterozygotes other than Y165C/G382D in
cases (1/12 in our original report) this is expected to have little
effect on the analysis that follows.
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In order to identify all relevant studies for the meta-analysis of the
effect of MUTYH on colorectal cancer risk, we searched ISI Web
of SCIENCE (http://wok.mimas.ac.uk/) and PUBMED (http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi) for the relevant literature
references. We found 55 studies (searching for ‘MYH and
colorectal cancer’), but only eight studies contained data that
met our inclusion criteria and thus were relevant to this meta-
analysis. These criteria were that patients had confirmed colorectal
adenocarcinoma (i.e. we excluded studies only based on the
multiple adenoma phenotype), and that the study reported
genotype data for cases and controls (Table 2). Table 3 includes
information on how the samples for each of the studies included in
the meta-analysis were collected. Individuals reported to have two
defects at MUTYH in the original report were classified as MM
(defects were considered pathogenic only if there was published
evidence of their pathogenicity), those with one defect as WM and
those with no detected defect as WW. In total, we assembled data
on 13449 people: 7273 colorectal cancer patients and 6176
population-based controls.
Statistical methods
The association of MUTYH with colorectal cancer was tested by
means of a standard w
2 test with 2 degrees of freedom, and
genotype relative risks (GRRs) were estimated as described
previously (Farrington et al, 2005).
We used the metabin option from the meta package of the R
software to perform the meta-analysis. We used the summary
measure relative risk and the inverse variance weighting to pool
studies. For mathematical reasons, cells with zero frequencies were
Table 1 Numbers of cases and controls, GRR and empirical 95% CI from the population-based study in Scotland: data from the original report, the
replication study and from the combined data
a
Farrington et al (2005) (P¼0.001) Replication (P¼0.09) All together (P¼0.0006)
Genotype No. of cases/controls GRR (95% CI) No. of cases/controls GRR (95% CI) No. of cases/controls GRR (95% CI)
MM 12/0 93.6 (42.6–213.2) 5/0 38.5 (10.6–110.1) 17/0 67.3 (35.3–128.7)
WM 45/28 1.4 (0.9–2.1) 18/20 0.8 (0.5–1.4) 63/48 1.13 (0.8–1.5)
WW 2160/1794 1.0 905/825 1.0 3065/2619 1.0
Total 2217/1822 928/845 3145/2667
aGRR is the genotype relative risk, CI is the confidence interval and P is the significance level for the test of association using a w
2 test with 2 degrees of freedom.
Table 2 Association between MUTYH and colorectal cancer: review and meta-analysis of published data
Study
No. of cases
MM/WM/WW
No. of controls
MM/WM/WW
Multiplicative model
RR (95% CI)
Dominant model RR
(95% CI)
Recessive model RR
(95% CI)
(Croitoru et al, 2004) 12/29/1197 0/21/1234 2.6 (1.6, 4.3) 2.0 (1.2, 3.4) N (2.84, N)
(Farrington et al, 2005) 12/45/2160 0/28/1794 2.0 (1.3, 3.2) 1.7 (1.1, 2.6) N (2.29, N)
(Peterlongo et al, 2005) 2/4/549 0/7/911 1.9 (0.7, 5.2) 1.4 (0.5, 4.2) N (0.31, N)
(Fleischmann et al, 2004) 2/5/351 0/0/97 4.1(0.2, 71.9) 4.2 (0.2, 72.2) N (0.05, N)
(Kambara et al, 2004) 0/2/90 0/1/52 1.2 (0.1, 12.6) 1.2 (0.1, 12.4) NA
(Wang et al, 2004) 2/10/432 0/4/309 2.5 (0.8, 7.5) 2.1 (0.7, 6.6) N (0.13, N)
(Enholm et al, 2003) 4/5/994 0/0/424 11.5 (0.7, 193.1) 8.1 (0.5, 139.0) N (0.27, N)
(Zhou et al, 2005) 0/6/432 0/3/466 2.1 (0.5, 8.6) 2.2 (0.5, 8.6) NA
Current replication study 5/18/905 0/20/825 1.3 (0.7, 2.3) 1.0 (0.6, 1.8) N (0.84, N)
Overall estimated effect 39/124/7110 0/84/6112 2.0 (1.6, 2.6) 1.6 (1.3, 2.1) N (8.63, N)
CI¼confidence interval; NA¼not available; RR¼relative risk. M vs W allele for the multiplicative model, MM and MW vs WW for the dominant model and MM vs MW and
WW for the recessive model. The recessive model RR confidence intervals were estimated using Fisher’s exact test.
Table 3 Information on the collection of samples of the studies included in the meta-analysis
Study Cases description Population Controls description Population
(Croitoru et al, 2004) Prospective series Regional Canadian Age and sex matched Same region of Canada
(Farrington et al, 2005) and
replication
Prospective series Scottish population Age, sex and region matched Scottish population
(Peterlongo et al, 2005) Consecutive series Regional USA Chosen from 17000 cohort
study as cancer free and age
matched
Same region USA and
ethnically matched.
(Fleischmann et al, 2004) Unrelated retrospective series Three regions of UK Spouses of individuals from
another cancer study
No information
(Kambara et al, 2004) Sporadic series Regional Australia Healthy blood donors Same region of Australia
(Wang et al, 2004) No information Regional USA Individuals negative by
colonoscopy
Same region of USA
(Enholm et al, 2003) Systematic series Finnish population Healthy blood donors No information
(Zhou et al, 2005) Sporadic series Three regions of Sweden Healthy blood donors Stockholm region
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recessive model with zero cell counts, we estimated exact
confidence intervals (CIs) using Fisher’s exact test.
RESULTS
Replication study
Table 1 shows the results obtained in this replication study, from
our previously published data and from the combined data set.
The replication study showed a significant homozygous MM effect
(Po0.05), and the results were suggestive of an association with
the MUTYH gene as a whole (P¼0.09). Combining these data
with our previously published data revealed a highly significant
association with MUTYH (P¼0.0006). However, a heterozygous
effect was not detected (Peterlongo et al, 2005; Tenesa et al, 2005).
Meta-analysis
First, we tested the overall association of the gene with colorectal
cancer assuming three plausible genetic models: multiplicative,
dominant and recessive. We found that the association was highly
significant (Pp0.0004) under the three genetic models considered.
We did not find significant heterogeneity between studies under
any of the models considered. The value of I
2, which quantifies
the level of heterogeneity on a continuous scale (Higgins and
Thompson, 2002), was 0% (95% CI: 0.0–48.7), 0% (95% CI: 0.0–
45.9) and 0% (95% CI: 0.0–39.8) for the multiplicative, dominant
and recessive model, respectively. Therefore, we assumed that the
effect was the same across studies and used a fixed effects model.
Note, however, that using a random effects model gave identical
results.
Next, we tested whether there was a homozygous (MM) and
heterozygous (WM) gene effect (Table 4). The overall homozygous
effect was highly significant (P¼0.0004), whereas the overall
heterozygous effect was almost significant (P¼0.09).
To address the possibility that methodological differences across
studies may have influenced these results, we pooled all available
data described in Table 2 and estimated the GRRs as before
(Farrington et al, 2005). We considered this was justified, as there
was no statistically significant heterogeneity among studies. We
performed the analyses both for all the 13449 samples (data set 1)
and separately for the 7657 samples not generated by our group
(data set 2). The 95% CI for the GRR estimates in the two data sets
overlapped both for MM and WM individuals. Data set 1 gave GRR
for the MM and WM equal to 117 (95% CI: 74–184) and 1.27 (95%
CI: 1.01–1.61), respectively. The overall MUTYH variant frequency
was 0.34%. Similarly, data set 2 gave GRR for the MM equal to 207
(95% CI: 109–415) and 1.47 (95% CI: 1.05–2.12) for WM. Both
data sets showed a highly significant (Po0.001) homozygous effect
and a heterozygous effect of borderline statistical significance
(Po0.05).
Finally, we tested whether there were differences in the effect of
Y165C and G382D mutations (Table 5). Estimates of the mono-
allelic effect were similar and not significantly different at the 5%
level. However, the bi-allelic effect was much larger for Y165C
carriers than for G382D carriers, although this difference was not
statistically significant.
DISCUSSION
This study confirms, in a combined data set of over 7000 cases
across several study populations, that the association between
variants in the MUTYH gene and colorectal cancer risk is valid.
Bi-allelic inactivation of the gene conferred a very large increase in
risk (GRR¼117) supporting its causal role in colorectal cancer,
whereas mono-allelic inativation of the gene conferred a moderate
increase in risk (GRR¼1.3). Confidence intervals for the estimate
of the risk associated with germline bi-allelic defects were wide,
even though the total sample size was over 13000 individuals. This
effect might be substantially overestimated if the proportion of
compound heterozygotes in the control sample was equal to the
case sample (i.e. 1/46), but we believe this is highly unlikely as we
Table 4 MUTYH genotype effect on colorectal cancer risk: review and
meta-analysis of published data
Heterozygous
(WM) effect
Homozygous
(MM) effect
a
Study RR (95% CI) RR (95% CI)
(Croitoru et al, 2004) 1.4 (0.8, 2.5) N (2.86, N)
(Farrington et al, 2005) 1.3 (0.8, 2.1) N (2.30, N)
(Peterlongo et al, 2005) 0.9 (0.3, 3.2) N (0.31, N)
(Fleischmann et al, 2004) 3.1 (0.2, 54.7) N (0.05, N)
(Kambara et al, 2004) 1.2 (0.1, 12.4) NA
(Wang et al, 2004) 1.8 (0.6, 5.6) N (0.14, N)
(Enholm et al, 2003) 4.7 (0.3, 84.7) N (0.28, N)
(Zhou et al, 2005) 2.2 (0.5, 8.6) NA
Current replication study 0.8 (0.4, 1.6) N (0.83, N)
Overall effect 1.3 (1.0, 1.7) N (8.63, N)
CI¼confidence interval; NA¼not available; RR¼relative risk.
a95% CI estimated
using exact methods (Fisher exact test).
Table 5 Counts of G382D and Y165C mutations reported in the published data and GRR
G382D Y165C
Study Cases Controls Cases Controls
(Croitoru et al, 2004) 4/21/1197 0/17/1234 2/8/1197 0/4/1234
(Farrington et al, 2005) 8/31/2160 0/20/1794 0/14/2160 0/8/1794
(Peterlongo et al, 2005) 1/2/549 0/5/911 0/2/549 0/2/911
(Fleischmann et al, 2004) 1/4/351 0/0/97 0/1/351 0/0/97
(Kambara et al, 2004) 0/2/90 0/0/52 0/0/90 0/1/52
(Wang et al, 2004) 0/5/432 0/2/309 1/5/432 0/2/309
(Enholm et al, 2003) 1/4/994 0/0/424 0/1/994 0/0/424
(Zhou et al, 2005) 0/2/432 0/1/466 0/4/432 0/2/466
Current replication study 2/15/905 0/14/825 2/3/905 0/6/825
Overall numbers 17/86/7110 0/59/6112 5/38/7110 0/25/6112
GRR (MM/WM/WW) 103.63/1.26/1 168.82/1.31/1
GRR 95% CI (MM/WM/WW) (55.26–188.61)/(0.96–1.68)/(1.00–1.00) (48.77–438.31)/(0.86–2.06)/(1.00–1.00)
CI¼confidence interval; GRR¼genotype relative risk.
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did not find any compound heterozygotes.
Similarly, mono-allelic defects are of borderline statistical
significance. This underscores the important role of meta-analyses
of large data sets from well-conducted studies to properly interpret
these relationships. It is difficult to assess whether differences in
the screening method employed by different studies might explain
the small heterozygous effect (i.e. not all studies did a systematic
screening of heterozygous individuals in order to discard other
possible disease variants), but additional support from other
studies (Jenkins et al, 2006) that used different methods and
samples suggest that the small heterozygous effect is real. Hidden
compound heterozygotes would further increase the numbers
required to assess whether there is indeed a heterozygous effect
because the heterozygous effect would be even smaller.
Our study confirms and provides more precise estimates for the
homozygous effect and strengthens the evidence for a weak
heterozygous effect. The study underscores some of the difficulties
of studying the role of low-frequency variants of small effect and
emphasises the need for international collaboration to achieve the
very large sample sizes required to identify these variants and
quantify their effects.
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